PARSIPPANY, N.J., July 21, 2025 /PRNewswire/ — Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has announced it successfully passed the U.S. Food and Drug Administration (FDA)’s on-site GMP audit with a “No Action Indicated” (NAI) result. This is the best possible result, confirming complete compliance with no objectionable conditions (“zero-deficiency”).

The FDA’s issuance of a Current Good Manufacturing Practice (CGMP) compliance notification and Establishment Inspection Report (EIR) formally recognizes Bloomage’s pharmaceutical quality system as fully aligned with international regulatory expectations. The recognition not only affirms Bloomage’s commitment to excellence in quality management but also significantly strengthens its position in global markets, providing international partners and customers with added confidence.

FDA Certification: The Global Gold Standard for Pharmaceutical Quality

The FDA is widely recognized as one of the most rigorous drug regulatory agencies in the world. Its authority stems from its comprehensive and strict oversight of the entire drug lifecycle, from research and development to manufacturing and distribution, encompassing areas such as data integrity, quality assurance, and risk management systems.

The five-day audit of Bloomage was conducted in accordance with ICH Q7 guidelines for active pharmaceutical ingredients (APIs) and covered six core systems: Quality, Facilities and Equipment, Materials, Production, Laboratory Control, and Packaging & Labeling. Additionally, the inspection included in-depth verification of computerized systems and electronic records.

Achieving a “zero-deficiency” result under this level of scrutiny demonstrates Bloomage’s precise operational control and its unwavering commitment to high-quality standards.

Notably, this is not the company’s first “zero-deficiency” outcome from a national regulator in a major global market. In February 2025, Bloomage also passed an on-site GMP inspection by the Ministry of Food and Drug Safety (MFDS) of South Korea. That three-day inspection, conducted by two official auditors, concluded with the best possible result, confirming full compliance with no objectionable conditions (“zero-deficiency”).

To date, Bloomage’s sodium hyaluronate API products have successfully passed five FDA inspections, one inspection by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and two MFDS inspections in Korea. These achievements not only demonstrate the company’s regulatory strengths, but also provide a solid compliance foundation for collaborations with partners around the world.

Sustained Quality, Global Trust: How Bloomage Scales with Precision and Compliance

Bloomage has become a trusted global supplier by delivering world-class product quality and a consistent track record of regulatory approvals. Its sodium hyaluronate APIs have obtained 34 registrations and filings across the European Union, United States, Japan, Korea, Canada, Russia, India, etc. This includes 11 Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) and 10 Drug Master File (DMF) filing with the U.S. FDA — making Bloomage one of the most comprehensively registered sodium hyaluronate suppliers in the world.

Bloomage has spent more than two decades providing high-quality, cutting-edge bioactive raw materials and tailored solutions to many of the world’s leading companies in sectors ranging from beauty & care and pharma & aesthetics to nutrition & health.

The company now operates a global marketing and supply network covering over 70 countries and regions, with subsidiaries established in the United States, France, Japan, Korea, and Singapore.

Bloomage continues to explore the potential of emerging markets by strengthening R&D and responding flexibly to evolving global demand. Its ability to allocate resources efficiently and tailor services to specific regional needs reflects its agility in navigating diverse market landscapes.

Certifications as a Strategic Foundation

Sustainable brand strength is not built on marketing alone. An integrated infrastructure of quality systems, reliable supply chains, and the ability to adapt to increasingly complex global regulatory environments is required.

For Bloomage, long-term investment in R&D and international certifications forms the foundation of its product excellence and market competitiveness. These efforts underpin the company’s ability to deliver superior products and maintain a trustworthy brand image.

Rather than viewing compliance as a cost, Bloomage sees it as a strategic moat. The company has built a full-chain system that integrates technical standards, quality control, and global regulatory alignment. This enables it to lead with substance, not slogans, and win trust in even the most competitive and tightly regulated markets.

About Bloomage

Since its founding in 2000, Bloomage has grown into a leading international company specializing in the research, development, production, and sale of hyaluronic acid and other bioactive substances for the pharmaceutical, cosmetic and functional foods industries. Bloomage’s commitment to quality, innovation, and sustainable innovations have established the company as a trusted name for some of the world’s most renowned brands. It now serves more than 4,000 customers in over 70 countries.
Learn more at Bloomage.com 

Media Contact
Cecilia Qian
cecilia@impact5r.com 

PHILADELPHIA, July 21, 2025 /PRNewswire/ — Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. 

Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster.

Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: “On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies.”

Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented: “I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company’s strong foundations and drive its next phase of growth.”

About Minaris Advanced Therapies:

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.

Minaris Advanced Therapies is a portfolio company of Altaris.

www.minaris.com

About Altaris:

Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com

Media Contact:

Tihesha Aaron

corp.communications@minaris.com

Dr. Orla Cloak, Recently Appointed Chief Executive Officer, Minaris Advanced Therapies

NEW YORK, July 21, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on July 21st

• Over the weekend, the White House reiterated its position on tariffs. U.S. Commerce Secretary Howard Lutnick said August first is the “hard deadline” for countries to begin payment.
• Corporate earnings season is ramping up with several companies including Alphabet and Tesla set to report this week. 59 S&P 500 companies have reported this season with 86% beating expectations.
• The FIFA World Cup 2026 New York/New Jersey host committee will ring the opening bell. Tammy Murphy, board chair, will do the honors as the world sits one year out from the final match in 2026.

Opening Bell
FIFA World Cup 26 NYNJ Host Committee will mark one year to the final match of the World Cup

Closing Bell
Western Union (NYSE: WU) celebrates its upcoming 175^th anniversary helping people around the world save, spend, and transfer money

Click here to download the NYSE TV App

UDAIPUR, India, July 21, 2025 /PRNewswire/ — India-based Hindustan Zinc Limited, a Vedanta Group company and the world’s largest integrated zinc producer, announced its financial results for the first quarter ended 30^th June 2025 on 18^th July 2025. The company registered its highest ever first quarter mined metal production of 265 KT. Also, the company clocked record quarterly alloy production from subsidiary Hindustan Zinc Alloys (HZAPL), taking overall share of value-added products to c.24%. The company registered the lowest ever first quarter zinc cost of production (COP)^{^} at US$ 1,010/MT, better 9% YoY. The company delivered a profit, beating estimates to US$ 261 million with an industry leading EBITDA margin of c.50%. Hindustan Zinc, amongst the top five silver producers globally, has witnessed continued significant contribution from the silver segment to profitability at c.41%.

Hindustan Zinc records lowest-ever first quarter cost of production

During the quarter, the company secured two critical mineral blocks, Potash in Rajasthan and Rare Earth Elements (REEs) in Uttar Pradesh. In the same period, the company’s renewable energy consumption increased to c. 19%, on track to progressively achieve 70% by FY28. Along with that, Hindustan Zinc’s Board approved the first phase of plans towards doubling production capacity with an investment of US$ 1.4 billion to set up a new 250 KTPA integrated smelting complex alongside similar expansion of mines & mills capacities. Historically, Hindustan Zinc has maintained investment grade rating ‘AAA’ and recently received ratings reaffirmation at CRISIL AAA/Stable/CRISIL A1+.

Arun Misra, Chief Executive Officer, said: “Delivering our highest-ever first quarter mined metal production at the lowest-ever zinc cost of production reflects our relentless focus on operational efficiencies and cost leadership. We have further strengthened our growth pipeline with Board approved Phase-1 of plans towards doubling the production capacity. Coupled with the addition of critical minerals blocks and rare earth elements, we are poised to transform into a multi-metal powerhouse, unlocking sustained value for our stakeholders.”

_{USD-INR rate is 85.57
^since underground transition}

About Hindustan Zinc Limited

Hindustan Zinc Limited, a Vedanta Group company, is the world’s largest integrated zinc producer and recognized as the world’s most sustainable metals & mining company by the S&P Global CSA 2024.

Disclaimer

This release contains forward-looking statements that may differ from actual results. We undertake no obligation to update them.

Building the world’s first “Technology + Governance” dual-wheel drive platform to promote implementable governance standards

HONG KONG, July 21, 2025 /PRNewswire/ — The AI for Human International Foundation (the “Foundation”) was officially established on July 9, 2025 with the goal of building the world’s first “Technology + Governance” dual-wheel drive platform in order to unite the strengths of all sectors to solve the ethical, regulatory and governance issues brought about by the rapid development of artificial intelligence, and to build a new paradigm for the governance and development of artificial intelligence.

The Foundation is co-founded by Mr. Nicholas Chan Hiu-fung, Hong Kong Deputy to the National People’s Congress, Ms. Sun Mingjun, President of the Zhongguancun Intelligent Artificial Intelligence Research Institute, and Mr. Fung Yui Kong, Founder of Pangaea Connectivity Technology Limited (Stock Code: 1473). The Foundation is a non-profit organization established for the purpose of integrating resources, introducing talents, and sharing technologies through marketization. Facing the global demand for AI technologies, the Foundation built the world’s first “technology + governance” dual-wheel drive platform, solving the ethical, regulatory, and governance issues brought about by the rapid development of AI, and formulating corresponding laws and policies to promote the advancement of AI technologies, so as to establish an open, safe, cooperative and shared international platform to promote the healthy development of global AI technologies.

Functions and missions of the Foundation:

1. To conduct in-depth research on the governance aspects of Artificial Intelligence in terms of data security, privacy protection and generative AI regulation, to propose effective governance and development solutions, and to actively publish reports to enhance the influence of the industry.
2. To organize Salon meetings around AI intellectual property to strengthen the exchange of AI intellectual property and increase the awareness of protection.
3. To launch industry surveys and research, form a working group composed of senior experts, draft industry standards and technical specifications, widely solicit opinions, and continuously improve standards and regulatory frameworks.
4. To construct an international exchange platform, organize scene matching, resource matching, etc., and host international conferences to promote the globalization of technology, information sharing and experience exchange, and to strengthen the cohesion of the industry.
5. To establish a talent exchange and training program to attract and cultivate highly skilled personnel to provide human resources assurance for the development of artificial intelligence.

Ms. Sun Mingjun, Chairman of the Foundation and President of the Zhongguancun Intelligent Artificial Intelligence Research Institute said, “The purpose of the Foundation is to address the global demand for AI technology, and then to bridge the gap between supply and demand for AI, such as governance, ethics, and global legal compliance, as well as technology, and how it can be deeply connected in different contexts. Based on the background of this industry, we initiated the establishment of the Foundation to realize the work of global artificial intelligence technology promotion.”

Mr. Nicholas Chan Hiu-fung, Honorary Founding Chairman of the Foundation and Hong Kong Deputy to the National People’s Congress, said, “In this era of artificial intelligence, we are all trying to explore the way forward. We are now in the era of Industry 4.0. In the supply chain and daily life, we are also exploring how to work more efficiently and economically. Artificial intelligence is very close and relevant to our lives. It requires the collaboration of many parties, including a sound policy environment, good laws and regulations, as well as talents, resources, technology, creativity and capital, etc. Hong Kong is endowed with these unique conditions. Hong Kong is a place where talents converge. When students and scientific research talents are learning and applying, it is very important to have a channel for the transformation of scientific research into application scenarios.”

Regarding the development potential of AI in the application landscape, Mr. Fung Yui Kong, Vice Chairman of the Foundation and Founder of Pangaea Connectivity Technology Limited, pointed out, “Artificial intelligence has developed particularly rapidly in the past two to three years due to the large-scale construction of data centers both in China and in the United States. Computing speed is the key in the development process. Power is of course the most important thing, and data speed also needs to be improved because computing is fast and furious. We believe that there are not many scenarios that apply to AI at the day-to-day level. We believe that there will be a wider range of applications in the next few years, and this application level will require a lot of computing power in the information center. We set up the Foundation at this time because we see that there is enormous room for development in the future”.

Regarding the Foundation’s future focus, President Sun said, “In the second half of this year, the Foundation will plan to release case reports on artificial intelligence + environmental protection governance and practices, as well as reports on artificial intelligence + healthcare governance and practices, etc. Through artificial intelligence, some practical cases such as environmental protection, sewage treatment and air treatment, etc., can be fundamentally resolved.  We hope to first use Hong Kong as a base, facing the world such as countries of the BRICS and the Belt and Road Initiative, etc., to fully promote the practice to the world, and initially set up a liaison mechanism to establish the artificial intelligence industry standards and evaluation platform, so that the whole society can build confidence in artificial intelligence to help this technology put into practice.”